109 studies found for:    Hemophilia: Clinical Trials
Show Display Options
Rank Status Study
21 Completed Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII
22 Completed Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: activated recombinant human factor VII;   Other: factor IX;   Drug: factor VIII
23 Completed Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Interventions: Drug: turoctocog alfa 2000 IU/vial;   Drug: turoctocog alfa 3000 IU/vial
24 Completed Trial of NovoSeven® in Haemophilia - Joint Bleeds
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: activated recombinant human factor VII;   Drug: Feiba VH
25 Completed
Has Results
A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A
Condition: Hemophilia A
Interventions: Biological: rFVIII (BAY81-8973) on demand;   Biological: rFVIII (BAY81-8973) prophylaxis low-dose;   Biological: rFVIII (BAY81-8973) prophylaxis high-dose
26 Completed Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Intervention: Drug: activated recombinant human factor VII
27 Recruiting BAY81-8973 Pediatric Safety and Efficacy Trial
Condition: Haemophilia A
Intervention: Biological: Recombinant Factor VIII (BAY81-8973)
28 Completed Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B;   Healthy
Interventions: Drug: NNC 0172-0000-2021;   Drug: placebo
29 Completed Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Drug: Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS
30 Recruiting Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
31 Recruiting Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
32 Completed Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII, long acting
33 Completed A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B;   Healthy
Interventions: Drug: activated recombinant human factor VII, long acting;   Drug: placebo
34 Completed Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Interventions: Drug: Advate®;   Drug: turoctocog alfa
35 Active, not recruiting Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
36 Completed Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: NNC 0128-0000-2011
37 Not yet recruiting Hemophilia Inhibitor Prevention (INHIBIT) Trial
Condition: Severe Hemophilia A
Intervention: Drug: Long-acting recombinant factor VIII Fc fusion protein
38 Completed Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration
Condition: Hemophilia A
Intervention: Biological: BAY94-9027 + Kogenate FS (Recombinant Factor VIII, BAY14-2222)
39 Terminated Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
Condition: Hemophilia A
Interventions: Drug: Rituxan;   Drug: prednisone
40 Completed Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A
Condition: Hemophilia A
Interventions: Genetic: ReFacto AF;   Genetic: B-Domain deleted Recombinant Factor VIII;   Genetic: BDDrFVIII

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years